Midstream unit operations: Unsung heroes in AAV process development

Wednesday, August 18th 2021

8:00 PDT; 11:00 EDT; 16:00 BST; 17:00 CEST

Gene therapy aims to provide cures for life-threatening diseases that currently rely on complex and expensive life-long medications presenting a significant opportunity for companies to help people to live better lives. Although the quest for a templated process to speed up in the race to commercialization has largely remained elusive, we are starting to see evidence of scientific data from the process development experts.

Midstream unit operations consist of steps such as cell lysis, DNA digestion and clarification. These are considered gold-standard unit operations in Adeno Associated Virus (AAV) production processes. Optimization of this midstream set of unit operations use should a mandatory step in process development. Collaborations between technology providers and gene therapy companies are critical in establishing know-how and solving the toughest challenges in gene therapy manufacturing. An example of a fruitful partnership between Merck and Precision BioSciences in developing an integrated approach to an AAV harvest step will be presented in this webinar.

  • Discover critical success factors for midstream AAV bioprocess steps including cell lysis, DNA digestion and clarification
  • Case studies from Precision BioSciences
  • DoE (design of experiment) approaches and data driven insights
  • Scale-up considerations for a commercial manufacturing process
Matthew Roach
AAV Process Development Team Leader
Precision BioSciences
View Biography
Ratish Krishnan
Senior Strategy Consultant, Novel Modalities BioProcessing Group
View Biography
Elisa Manzotti
CEO and Founder
BioInsights Publishing
View Biography

Registration Details:

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.

(*) denotes required form field(s)